NCB1824, a small-molecule inhibitor of both JAK1 and JAK2, suppresses levels of phosphorylated STAT3 in subjects with wild-type JAK2 or with the gain-of-function V617F JAK2 mutation, as revealed in a phase 1–2 clinical trial of myelofibrosis patients. This evidence concerns the gene JAK2 and myelofibrosis.